Eli Lilly and Company (NYSE:LLY) Shares Acquired by Avior Wealth Management LLC

Avior Wealth Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 32.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 6,515 shares of the company’s stock after acquiring an additional 1,580 shares during the quarter. Avior Wealth Management LLC’s holdings in Eli Lilly and Company were worth $5,069,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Simon Quick Advisors LLC raised its stake in shares of Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares in the last quarter. Independent Advisor Alliance raised its position in Eli Lilly and Company by 1.7% in the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock valued at $18,810,000 after purchasing an additional 544 shares in the last quarter. Apexium Financial LP boosted its stake in shares of Eli Lilly and Company by 1,819.1% in the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock valued at $6,667,000 after buying an additional 10,842 shares during the period. Clear Harbor Asset Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth about $363,000. Finally, Terril Brothers Inc. increased its stake in shares of Eli Lilly and Company by 113.2% during the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after buying an additional 429 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $914.57 on Friday. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $918.50. The firm has a 50-day simple moving average of $831.69 and a 200-day simple moving average of $751.25. The company has a market capitalization of $869.22 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.99 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period last year, the firm earned $1.62 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 8,848 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the transaction, the insider now directly owns 97,299,772 shares in the company, valued at $89,059,454,309.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the transaction, the insider now directly owns 97,299,772 shares in the company, valued at approximately $89,059,454,309.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 858,742 shares of company stock worth $735,573,781. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LLY. Bank of America reiterated a “buy” rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a research note on Monday, June 24th. Morgan Stanley reiterated an “overweight” rating and set a $1,023.00 target price on shares of Eli Lilly and Company in a research note on Friday. Jefferies Financial Group raised their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, July 1st. Finally, The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $816.78.

View Our Latest Stock Analysis on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.